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The Mastocytosis Society Survey on Mast Cell Disorders:
Patient Experiences and Perceptions
Susan Jennings, PhDa, Nancy Russell, DrPHa, Blair Jennings, BSa, Valerie Slee, RN, BSNa, Lisa Sterling, BSa,
Mariana Castells, MD, PhD, FAAAAIb, Peter Valent, MDc, and Cem Akin, MD, PhD, FAAAAIb Hastings, Neb; Boston, Mass;
and Vienna, AustriaWhat is already known about this topic? Mastocytosis and mast cell activation syndromes are rare diseases or entities
manifested by symptoms that mimic allergies, anaphylaxis, and chronic conditions, and can go unrecognized for many
years with unnecessary suffering by patients.
What does this article add to our knowledge? This article provides the ﬁrst description of the US mastocytosis and mast
cell activation syndromes population based on a survey of patients. Results include the length of time to diagnosis,
disease impact, symptoms, speciﬁc organ systems affected, and associated conditions, such as allergies and triggers.
How does this study impact current management guidelines? This article will provide clinicians with an evidenced-
based rationale for a focused investigation of the wide range of symptoms and experiences of patients with suspected or
conﬁrmed mastocytosis and/or mast cell activation syndromes.BACKGROUND: Mast cell diseases include mastocytosis and
mast cell activation syndromes, some of which have been shown
to involve clonal defects in mast cells that result in abnormal
cellular proliferation or activation. Numerous clinical studies of
mastocytosis have been published, but no population-based
comprehensive surveys of patients in the United States have been
identiﬁed. Few mast cell disease specialty centers exist in the
United States, and awareness of these mast cell disorders is
limited among nonspecialists. Accordingly, information
concerning the experiences of the overall estimated population of
these patients has been lacking.
OBJECTIVE: To identify the experiences and perceptions of
patients with mastocytosis, mast cell activation syndromes, and
related disorders, The Mastocytosis Society (TMS), a US basedaThe Mastocytosis Society, Inc, Hastings, Neb
bDivision of Rheumatology, Immunology, and Allergy, Department of Medicine,
Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass
cDivision of Hematology and Hemostaseology, Department of Internal Medicine I,
Medical University of Vienna, Vienna, Austria
This work was primarily conducted through volunteer efforts of The Mastocytosis
Society (TMS) Research Committee and Board of Directors, with scientiﬁc and
medical questions resolved by those with relevant background and expertise.
Minimal costs of postage and online survey and database hosting were supported
by TMS. The authors obtained no funding for activities related to this report.
Grants from TMS not directly related to conducting, analyzing, or reporting of this
patient survey were received by C. Akin and M. Castells in the years before the
survey and by P. Valent after survey closure. M. Castells, P. Valent, and C. Akin
are TMS Medical Advisory Board members.
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70patient advocacy, research, and education organization,
conducted a survey of its members and other people known or
suspected to be part of this patient population.
METHODS: A Web-based survey was publicized through clinics
that treat these patients and through TMS’s newsletter, Web site,
and online blogs. Both online and paper copies of the
questionnaire were provided, together with required statements
of consent.
RESULTS: The ﬁrst results are presented for 420 patients. These
results include demographics, diagnoses, symptoms, allergies,
provoking factors of mast cell symptoms, and disease impact.
CONCLUSION: Patients with mastocytosis and mast cell
activation syndromes have provided clinical specialists,
collaborators, and other patients with information to enablehas consultant arrangements with Merck, Novartis, and Genentech; and is
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Mature mast cells (MC) are found around blood vessels in all
tissues and also where the body interacts with its surroundings,
well positioned for quick reaction to environmental threats. MC
disorders (MCD) include diseases that involve abnormal prolif-
eration and/or activation of these cells. Patients may have
primary MCD or other MC activation syndromes (MCAS),1-4
sometimes referred to as MC activation disorders (MCAD).
People with MCD may be at risk for anaphylaxis and chronic
and debilitating symptoms. MCD terminology has evolved as
researchers have gained new insights. Clonal MC carrying
D816V or other KIT tyrosine kinase mutations have been
identiﬁed in patients with primary MCD, including mastocytosis
and monoclonal MCAS.1,2,4-6 Cutaneous mastocytosis (CM)
usually occurs in children, whereas systemic mastocytosis (SM),
which involves internal organs, is generally diagnosed in adults.
Criteria for diagnosing MC activation (MCA) have recently
been proposed in a consensus report.2 MCA occurs by both IgE-
dependent and independent mechanisms, which cause MC to
release mediators, including histamine, tryptase, arachidonic acid
metabolites (eg, prostagladins and leukotrienes), cytokines, and
chemokines, which initiate or exacerbate symptoms. Primary
MCAS is associated with MCA symptoms and the presence of
World Health Organization criteria for SM.2 MCA can also be
present in mastocytosis and lead to reduced quality of life.2 In
other patients, an underlying allergy may be found to cause the
MCA; these patients have secondary MCAS. Patients with MCA
symptoms without deﬁned clonal MC, or other underlying
conditions that might lead to MCA, are diagnosed as having
idiopathic MCAS.2
The Mastocytosis Society, Inc (TMS) (www.tmsforacure.org),
a US-based patient organization, provides support, research, and
advocacy for those patients with mastocytosis, MCAS, and
Open access under CC BY license.related disorders. This article describes a Web-based survey by
TMS for people with these disorders. Demographics, diagnoses,
symptoms, allergies and/or intolerances, provoking factors of
MC symptoms, preventive carrying of epinephrine and/or
medical identiﬁcation, and disease impact on lives are reported.
Additional concerns will be described in future reports.
METHODS
Study design
The cross-sectional survey questionnaire was developed by the
TMS Research Committee (S.J., N.R., B.J.) and executive board
members (V.S., L.S.) by using preliminary questions and advice
provided by MC specialists (P.V., C.A.). A copy of the survey
questionnaire is provided as Figure E1 (in this article’s Online
Repository at www.jaci-inpractice.org). The survey was open to
patients who identiﬁed themselves as having an MCD and who
were not participating in a similar concurrent European Union
survey. Caregivers were instructed to answer all questions for
minors and other patients unable to answer for themselves.
Web site and database development. Survey questions
were converted into an online format (B.J., S.J.). An external
company hosted the Web survey, backed by an onsite-encrypted,
secure database that was moved to a secure system for analysis
after survey closure.
Survey population, recruitment, and data collection
Population. Patients of all ages, or patient caregivers, living in
or outside the United States, with mastocytosis, MCAS and/or
MCAD, or other MCDs were invited to complete the survey
irrespective of TMS membership.
Publicity. The survey was publicized in the month before its
posting through a TMS publication, The Mastocytosis Chronicles,
notices in clinics of physicians who work with the society, support
groups, the TMS Web site, and online MCD-related blogs.
Access. The survey was posted online through a TMS Web
site link, between April 15 and May 24, 2010, with paper copies
mailed upon request. Entry required checkbox selection that
indicated respondents’ understanding of survey conﬁdentiality
and procedures. After providing consent, the entrants received
a unique and conﬁdential user number and password, which
allowed them to stop during the survey and return later. A “no
charge” telephone number and e-mail address were posted for
help with completing responses.
Data evaluation. Valid responders were deﬁned as those who
answered at least some questions beyond the opening section for
Demographics and Diagnosis. Data evaluation was performed by
using Excel and Access software (Microsoft Corp, Redmond,
Wash). The variable “years until diagnosis” was calculated by
subtracting the year of symptoms onset from the year of diag-
nosis. Some percentages do not sum to exactly 100% due to
rounding. In certain cases, percentages less than 5% or missing
responses are not reported.
When respondents selected multiple diagnosis options, they
were classiﬁed as follows: urticaria pigmentosa (UP) or another form
ofCM, along withMCAS and/orMCADor idiopathic anaphylaxis
(IA), was classiﬁed as CM; UP plus SM was classiﬁed as SM; UP
plus SM and MCAS and/or MCAD, was classiﬁed as SM. Those
who marked both IA and MCAS and/or MCAD were classiﬁed in
FIGURE 1. Reported diagnoses of 420 survey respondents, reporting each diagnosis type. “Diagnosis not determined” also includes
those who were “not sure.”
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or MCAD who did not mark another mastocytosis category or IA.
RESULTS
Demographics
A total of 530 people entered the survey, of whom 41 did not
answer any questions and 69 only completed the initial Demo-
graphics and Diagnosis section. Eliminating these groups yielded
420 valid responders. Most (370 [88.1%]) completed the survey
for themselves. Because anonymity and conﬁdentiality were
assured, it is not possible to report proportion of members versus
other responders nor their places of residence. However, care in
the United States was received by 84.3% (317 of 376 respon-
dents). There were 62.6% female respondents, 22.1% male
respondents, and 15.2% not stated. Ages of 416 subjects who
provided birth years ranged from 1 to 80 years with an average of
44.8 years and a median of 48 years. Most (393 [93.6%]) were
white, with 6.0% Native American, Hispanic, or other ethnic or
mixed groups.
Diagnoses
Diagnoses were determined (Figure 1) and reported as
“conﬁrmed by test results” by 89.5% of the 315 with CM or
SM. Of 100 people who listed CM, 35 were younger than age 18
years, of whom just one listed having a bone marrow biopsy.
Only 40% of the 65 adults with CM reported having this biopsy.
Of 215 who reported SM (4 of whom were younger than age 18
years), 7.0% listed aggressive SM, 6.0% also noted an associated
hematologic disorder, and one had MC leukemia (0.5%). Bone
marrow biopsies were reported by 72% of the total SM group.
Additional details on diagnoses can be found in the Online
Repository. Years that elapsed between the ﬁrst symptoms and
the diagnosis for 341 people who provided these data ranged
from less than 1 year to 50 years, with an average of 6.5 years and
a median of 3 years.
Symptoms related to MCD
Severity (extreme, moderate, a little bit, or not at all) and
frequency (daily, occasionally, rarely, or never) of 29 different
MCD symptoms were queried and proportions with any severity
(extreme, moderate, or a little bit) or moderate or extreme
severity, in total or on a daily or occasional basis, are shown in
Tables I and II. More than two-thirds of the respondents listed
any severity of itching, ﬂushing, fatigue, and stomach pain. Morethan half also noted these symptoms daily or occasionally with
moderate or extreme severity, with fatigue and stomach pain
noted most frequently. Daily extreme severity of fatigue was
experienced by 91 respondents (21.7%) and stomach pain by 62
(14.8%) (for this and other extreme severity symptom data, see
Tables E1 and E2 in this article’s Online Repository at www.jaci-
inpractice.org). Other notable symptoms included brain fog or
cognitive difﬁculties, diarrhea, headache, joint pain, UP rash or
telangiectasia macularis eruptiva perstans eruptions, light-head-
edness or syncope, abdominal bloating, anxiety, and bone and
lower abdomen pain.
Allergies
Of the initial 420 participants, 384 (91.4%) answered ques-
tions about allergies. Most (255 [66.4%]) recalled having allergy
testing, of whom 200 (78.4%) recalled a skin test either alone
(87 [34.1%]) or in addition to a RAST or other unspeciﬁed
allergy tests (114 [44.7%]). Forty-three people (16.9%) did not
recall having a skin test but did recall having a RAST or other
blood test with or without other allergy tests.
The survey queried participants on “allergies,” including
testing results and whether those allergies “cause problems,” with
or without a positive test. More than half of the 384 allergy
section respondents (224 [58.3%]) reported drug allergies based
on positive allergy tests (63 [16.4%]) and/or problems caused by
drugs (142 [37.0%]). More than half (223 [58.1%]) reported
allergies to environmental substances and/or inhalants; 154
tested positive (40.1%), and 163 noted that they caused prob-
lems (42.2%). Half (193 [50.3%]) reported food and beverage
allergies, 89 reported a positive test (23.2%), and 146 noted
problems caused by foods or beverages (38.0%). (Percentages of
speciﬁc substances and categories listed by respondents for the
above allergen types are presented in Tables E3-E5 in this arti-
cle’s Online Repository at www.jaci-inpractice.org). Allergies to
insect stings were reported by 109 people (28.4%); 54 recalled
a positive insect venom allergy test (14.1%), and 93 noted that
insect stings caused problems (24.2%). Some allergy section
respondents (45 [11.7%]) reported a latex allergy; 18 recalled
a positive test (4.7%), whereas 40 noted that they had problems
with latex (10.4%). A positive allergy test for at least one allergen
type that TMS queried was listed by 207 respondents (53.9%).
Allergen immunotherapy (“allergy shots”) was received by 82
allergy respondents (21.4%), of whom 47 tolerated this therapy
(57.3%). However, only 21 who tolerated injections found them
TABLE I. Severity and frequency of skin and gastrointestinal symptoms among 420 respondents
Symptom
Severity
Any* Moderate or extreme
Total responses, no. (%) Daily or occasionally, no. (%)† Total responses, no. (%) Daily or occasionally, no. (%)z
Skin
Flushing 321 (76.4) 264 (82.2) 239 (56.9) 216 (90.4)
Itching 333 (79.3) 292 (87.7) 238 (56.7) 226 (95.0)
UP rash or TMEP eruptions 257 (61.2) 223 (86.8) 196 (46.7) 180 (91.8)
Darier sign 216 (51.4) 183 (84.7) 152 (36.2) 141 (92.8)
Dermatographism 222 (52.9) 176 (79.3) 133 (31.7) 122 (91.7)
Rashes, other than UP or
TMEP
184 (43.8) 140 (76.1) 128 (30.5) 115 (89.8)
Gastrointestinal (other than pain)
Diarrhea 277 (66.0) 237 (85.6) 220 (52.4) 203 (92.3)
Abdominal bloating 256 (61.0) 217 (84.8) 186 (44.3) 174 (93.5)
GERD 241 (57.4) 197 (81.7) 164 (39.0) 153 (93.3)
Nausea and vomiting 226 (53.8) 161 (71.2) 156 (37.1) 131 (84.0)
GERD, Gastroesophageal reﬂux.
*Any severity: extreme, moderate, or a little bit.
†The percentage of the total with any severity.
zThe percentage of the total with moderate or extreme severity.
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majority of the 57 survey participants who wrote of speciﬁc
allergen immunotherapy types noted injections against inhalant
and/or environmental allergens (47 [82.5%]), whereas 14%
noted venom immunotherapy and 3.5% listed drugs. Although
not standard for treatment of food allergies, 7.0% listed “allergy
shots” for food immunotherapy.
Triggers and/or provoking factors
Common triggers for MCA symptoms were provided in
a checklist, along with an open-ended “additional triggers”
question. Of 382 remaining participants, 366 (95.8%) checked
or listed triggers (Figure 2). Additional trigger details are listed in
Table E6 (in this article’s Online Repository at www.jaci-
inpractice.org). Insect stings were reported as triggers by 128
respondents, of whom, 93 had previously reported positive tests
or problems with stings in the allergy section. Sixteen other
participants who had previously noted positive sting allergy tests
or problems did not report them as triggers. In total, 144
respondents (37.7%) listed insect stings as a trigger, recalled
a positive insect sting allergy test, and/or noted in the Allergy
section that they “caused problems.”
Self-injectable epinephrine and medical alert
identification
More than three-fourths (305 [77.0%]) of 396 respondents
had a prescription for self-injectable epinephrine, and 239
(60.4%) always carried the medication. More than half (193
[50.9%]) of 379 respondents carried medical alert jewelry or
cards. Most (341 [90.0%]) were interested in carrying a regional
or global identiﬁcation card for MCD.
Living with an MCD
Most of the 379 respondents who answered the question
about overall MCD emotional impact on their lives felt it
impacted them either extremely (154 [40.6%]) or moderately
(134 [35.4%]), whereas 15.6% noted its impact as a little bit,
and 3.4% felt no impact. The greatest single distress-causingaspect of living with an MCD was the unpredictability of
symptoms (95 [25.1%]), followed by gastrointestinal symptoms
(17.9%), an inability to work or to participate in daily living
activities (15.3%), pain (12.9%), anaphylactic episodes (12.1%),
fatigue (10.3%), and fear or anxiety (4.2%). Relative severity
regarding coping with each aspect was ranked as extreme,
moderate, a little bit, or not at all. The relative proportions of
those affected extremely, moderately, or a little bit for each aspect
of life with a MCD are illustrated in Figure 3. More than 60% of
respondents were affected either moderately or extremely
regarding their need for coping with unpredictability of symp-
toms, gastrointestinal problems, and fatigue.
Opinions on disease classification
Responses to questions regarding opinions on MCD classiﬁ-
cation are presented in the Online Repository.
DISCUSSION
Reports concerning patients with MCD have noted the mean
time from symptom onset to diagnosis of nearly 3 and up to 9.5
years,7-9 and this duration also was extensive for TMS survey
respondents (mean, 6.5 years; median, 3 years). However, identi-
ﬁcation of large groups of these patients is challenging due to
several factors: symptoms that can masquerade as other disorders
and diseases,2 the seeming rarity of these disorders, limited specialty
center locations, and the evolving diagnostic and classiﬁcation
criteria. This survey was conducted as a collaboration between
TMS, with its large patient network, and MCD specialists in
preparation for the Year 2010 Working Conference on MCD.2
Two large European registries have provided previous estimates
of patient experiences: REMA (Red Española de Mastocitosis),
a Spanish network for mastocytosis10 and AFIRMM (Association
Française pour les Initiatives de Recherche sur le Mastocytes et les
Mastocytoses), a French mastocytosis organization.11 Although
numerous clinical studies and a survey that focused on autism12
have been published, no previous in-depth survey of US patients
with mastocytosis, MCAS, and related MCD has been identiﬁed.
FIGURE 2. The percentage of 366 respondents who selected or listed specific trigger types. Commonwrite-in triggers were various foods
(31.1%), cold (13.9%), food additives (9.3%), friction and/or pressure (8.7%), fatigue (6.8%), and chemicals (4.9%). Less common
write-in triggers are provided in Table E6.
TABLE II. Severity and frequency of pain and other symptoms among 420 respondents
Symptom
Severity
Any* Moderate or extreme
Total responses, no. (%) Daily or occasionally, no. (%)† Total responses, no. (%) Daily or occasionally, no. (%)z
Pain
Stomach 306 (72.9) 275 (89.9) 253 (60.2) 244 (96.4)
Lower abdomen 237 (56.4) 202 (85.2) 194 (46.2) 179 (92.3)
Joint 258 (61.4) 228 (88.4) 193 (46.0) 188 (97.4)
Bone 237 (56.4) 197 (83.1) 190 (45.2) 166 (87.4)
Muscle, nerve, connective tissue 210 (50.0) 185 (88.1) 166 (39.5) 158 (95.2)
Upper abdomen 195 (46.4) 159 (81.5) 151 (36.0) 138 (91.4)
Chest 154 (36.7) 96 (62.3) 96 (22.9) 73 (76.0)
Other
Fatigue 320 (76.2) 296 (92.5) 262 (62.4) 255 (97.3)
Headache 267 (63.6) 202 (75.7) 216 (51.4) 182 (84.3)
Brain fog and/or cognitive
difﬁculties
281 (66.9) 242 (86.1) 193 (46.0) 184 (95.3)
Lightheadedness/syncope 257 (61.2) 182 (70.8) 185 (44.0) 146 (78.9)
Weakness 225 (53.6) 173 (76.9) 171 (40.7) 149 (87.1)
Anaphylactic shock 175 (41.7) 82 (46.9) 158 (37.6) 80 (50.6)
Anxiety 255 (60.7) 190 (74.5) 156 (37.1) 146 (93.6)
Depression 207 (49.3) 148 (71.5) 121 (28.8) 111 (91.7)
Wheezing or asthma 186 (44.3) 125 (67.2) 111 (26.4) 92 (82.9)
Angioedema 146 (34.8) 83 (56.8) 107 (25.5) 66 (61.7)
High blood pressure episodes 123 (29.3) 93 (75.6) 89 (21.2) 72 (80.9)
Cardiac 120 (28.6) 83 (69.2) 82 (19.5) 66 (80.5)
*Any severity: extreme, moderate, or a little bit.
†The percentage of the total with any severity.
zThe percentage of the total with moderate or extreme severity.
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US survey of patients with these disorders.
This survey has several strengths. Key strengths are the 420
valid responders and high survey completion rate. Internet avail-
ability allowed participation of patients not treated at specialty
centers. The results provide a realistic account of problems and
demographics of those who present to medical providers with
a possible MCD diagnosis. Also, the survey was not funded by any
entity with a commercial or ﬁnancial proﬁt interest.Several weaknesses inherent to all population-based surveys
without medical professional assistance exist.13 Some respondents
may have had other diseases, and even some respondents who
actually had MCD may have reported symptoms or problems not
related to their MCD. People who entered the survey may have
tended to be those who were more active in online discussion and
support groups, and/or had more severe problems.13 Certain
responses would have been subject to limitations of patient recall
and bias, for example, interpretation of information received from
FIGURE 3. The percentages that represent aspects of life with a MCD among 379 respondents selecting extreme, moderate, or a little
effect regarding coping. The percentages are not displayed for those who selected “not at all” (4% to 5% did not answer these ques-
tions). *All numbers represent percentages.
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a medically accurate database, which would have required a review
of patient medical records bymedical professionals, was beyond the
intention and realistic expectations of this survey. A comparison of
this survey sample with another sample without MCD would have
been ideal; however, choosing such a sample would have been
extremely complex and beyond the scope and resources of TMS.
Because of these limitations, caution must be used when
comparing results of this survey with other studies.3,8,10,11,14-19
Nearly one-third of survey respondents who reported a diag-
nosis of mastocytosis were determined to have CM without SM;
however, only 40% of the adults with CM reported having had
a bone marrow biopsy. Even when bone marrow biopsies are
performed, the biopsies or associated laboratory studies may be
performed incorrectly. Even if they are performed appropriately,
mastocytosis can be missed20; accordingly, it is possible that this
survey underestimates the percentage of patients with SM.
It is interesting to note that the case-controlled AFIRMM study
mentioned above identiﬁed similar percentages regarding speciﬁc
symptoms for patients who experienced any severity (TMS) or any
disability (AFIRMM) for the following: fatigue, itching, headache,
bone pain, depression, and nausea and/or vomiting11 In both
analyses, these numbers identify all the patients who experienced
a given symptom, despite the level of severity or disability. Other
related symptoms with similar frequencies, but different query
terms, include the following: for TMS (AFIRMM), wheezing and/
or asthma (dyspnea and/or bronchreactivity), stomach pain
(epigastric pain), and brain fog and/or cognitive difﬁculties
(memory loss). AFIRMM identiﬁed 76% with any disability from
muscle and joint pain, cramps, whereas TMS separately queried
joint and muscle, nerve, and/or connective tissue pain. In the TMS
analysis, yes answers to either or both questions were combined,
which yielded 66.7% (280 respondents).
Two symptoms (any severity and/or any disability) with
similar patient queries were reported at higher levels to TMS:
ﬂush (76.4%, TMS; 52%, AFIRMM) and diarrhea (66.0%,
TMS; 35%, AFIRMM). Although the reasons for these differ-
ences are unknown, they may relate to different survey methods
and/or populations queried. Gastrointestinal symptoms were
experienced by 65% of patients with mastocytosis from a largeUS clinic.8 Various gastrointestinal symptoms of any severity
were experienced by 53.8% to 66.0% of TMS survey respon-
dents and required moderate or extreme coping for 65.5%.
Many patients with MCD have more than one condition, for
example, mastocytosis with allergy, and coexistence can aggravate
symptoms of MCA. Increased awareness of such coexistence may
help in the diagnosis and management of these patients. The
REMA study in Spain reported that allergy symptoms were
suggested in 57% of adult patients with mastocytosis; however,
true allergy prevalence (clinical symptoms related to speciﬁc IgE)
in the Spanish study was actually 23.9%, similar to that of the
general Spanish population.10 A US-based study reported that
31% of 48 adult patients with mastocytosis had a history of
allergic diseases or food allergy.15 A study of 120 German
patients with mastocytosis found a history of allergic diseases at
levels no higher than the general population (28% in adults).16
The TMS survey sections for allergies and triggers presented
a challenge in that patients may have been unable to differentiate,
without testing, between allergies and nonallergic intolerances or
triggers and/or provoking factors.2,16 Although clinical veriﬁcation
of IgE-mediated allergies was not possible, more than half of the
TMS allergy section respondents reported a positive allergy test for
at least one of the allergen types queried. Interestingly, high levels
of allergy and/or intolerance were found for food and/or beverages
(50.3% of respondents) and drugs (58.3%), similar to the
AFIRMM survey (61% reporting any disability from food allergy/
intolerance and 56% from drug allergy).11 Nearly all respondents
noted at least one MCD symptom trigger, and many provoking
factors were similar to reports found in the literature.3,4,6,9,16,21,22
Anaphylaxis rates for speciﬁc MCD patient populations may
be inﬂuenced by sex, age, MCD classiﬁcation, and the presence
of skin lesions8,10,11,16,18,23 and have been reported at rates up to
49% in adult patients with mastocytosis.16 In addition to food
and drug reactions, reports indicate 20% to 30% of patients with
mastocytosis experience insect venom-induced anaphylaxis.16,24
The TMS survey used the term anaphylactic shock along with
a severity scale, which, although medically incorrect, may have
been interpreted by patients as “anaphylaxis.” Anaphylactic
shock of any severity was reported by 175 TMS survey respon-
dents (41.7%). The AFIRMM study identiﬁed 44% who
J ALLERGY CLIN IMMUNOL PRACT
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study reported that unconsciousness was experienced in 53% of
adult patients with mastocytosis and with anaphylaxis.16
Although “unconsciousness” was not queried in the TMS survey,
109 people (26.0% of respondents) had experienced anaphylactic
shock with extreme severity. In addition, 28.2% of participants
noted that they were affected either moderately or extremely
regarding coping with anaphylactic episodes. Although patients
with mastocytosis and related MCD have increased anaphylaxis
risk,10,16,25 this survey found only slightly more than half of the
respondents always carry medical alert jewelry and/or cards or
self-injectable epinephrine. Survey responses regarding symptom
relief medications were too complex to include in this report.
However, the authors note that cytoreductive agents are generally
not used to treat indolent SM. Medication recommendations are
available and depend on MCD type.1,2,9,18,26-29
The ﬁndings of this survey highlight a need for education of
physicians in multiple disciplines, improved methods for recog-
nition of patients with potential MCD and clear criteria for
diagnosing MCD. Survey results were reported to specialists at
the 2010 MCD Working Conference. The conference report
includes proposed disease deﬁnitions, classiﬁcations, and diag-
nostic criteria.2 Patient priorities identiﬁed through this survey,
and a similar unpublished survey of patients in the European
Union also were included.2 It is hoped that this TMS survey will
help MCD specialists, other physicians, and patients to better
understand the experiences and perceptions of those living with
mastocytosis, MCAS, and related disorders.
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